-
Je něco špatně v tomto záznamu ?
Anti-domain 1 β2 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro
G. Manukyan, A. Martirosyan, L. Slavik, S. Margaryan, J. Ulehlova, Z. Mikulkova, A. Hlusi, T. Papajik, E. Kriegova,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
SCS 18T-1F396
State Committee of Science
MZ CR VES15-28659A, in part IGA UP_2018_016
Ministerstvo Zdravotnictví Ceské Republiky
MH CZ - DRO (FNOL, 00098892).
Ministerstvo Zdravotnictví Ceské Republiky
NLK
BioMedCentral
od 2010-05-01 do 2021-12-31
Free Medical Journals
od 2010
PubMed Central
od 2010 do 2021
Europe PubMed Central
od 2010
ProQuest Central
od 2010-05-01 do 2021-12-31
Open Access Digital Library
od 2010-01-01
Springer Nature OA/Free Journals
od 2010-05-01 do 2021-12-31
- Publikační typ
- časopisecké články MeSH
BACKGROUND: β2-Glycoprotein I (β2GPI) represents the major antigenic target for antiphospholipid antibodies (aPL), with domain 1 (D1) being identified as a risk factor for thrombosis and pregnancy complications in APS. We aimed to analyse the ability of aPL, and particularly anti-D1 β2GPI, to stimulate prothrombotic and proinflammatory activity of immune cells in vitro. METHODS: Peripheral blood mononuclear cells (PBMCs) from 11 healthy individuals were incubated with: (1) "anti-D1(+)"-pooled plasma derived from patients suspected of having APS contained anticardiolipin antibodies (aCL), lupus anticoagulant (LA), anti-β2GPI and anti-D1 β2GPI; (2) "anti-D1(-)"-pooled plasma from patients suspected of having APS contained aCL, LA, anti-β2GPI, and negative for anti-D1 β2GPI; (3) "seronegative"-negative for aPL. RESULTS: The presence of anti-D1(+) and anti-D1(-) plasma resulted in increased HLA-DR and CD11b on monocytes. While only anti-D1(+) plasma markedly increased the percentage and median fluorescence intensity (MFI) of CD142 (tissue factor, TF) on monocytes in comparison with those cultured with anti-D1(-) and seronegative plasma. Anti-D1(+) plasma resulted in increased percentage and MFI of activation marker CD69 on NK and T cytotoxic cells. Expression of IgG receptor FcγRIII(CD16) on monocytes and NK cells was down-regulated by the anti-D1(+) plasma. CONCLUSIONS: Taking together, our study shows the ability of patient-derived aPL to induce immune cell activation and TF expression on monocytes. For the first time, we demonstrated the influence of anti-D1 β2GPI on the activation status of monocytes, NK and cytotoxic T cells. Our findings further support a crucial role of D1 epitope in the promotion of thrombosis and obstetrical complications in APS.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005083
- 003
- CZ-PrNML
- 005
- 20210121103837.0
- 007
- ta
- 008
- 200511s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13317-020-00128-y $2 doi
- 035 __
- $a (PubMed)32127041
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Manukyan, Gayane $u Laboratory of Molecular and Cellular Immunology, Institute of Molecular Biology NAS RA, 7 Hasratyan St., 0014, Yerevan, Armenia. gaya.manukyan@gmail.com. Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc and Faculty Hospital, Olomouc, Czech Republic. gaya.manukyan@gmail.com.
- 245 10
- $a Anti-domain 1 β2 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro / $c G. Manukyan, A. Martirosyan, L. Slavik, S. Margaryan, J. Ulehlova, Z. Mikulkova, A. Hlusi, T. Papajik, E. Kriegova,
- 520 9_
- $a BACKGROUND: β2-Glycoprotein I (β2GPI) represents the major antigenic target for antiphospholipid antibodies (aPL), with domain 1 (D1) being identified as a risk factor for thrombosis and pregnancy complications in APS. We aimed to analyse the ability of aPL, and particularly anti-D1 β2GPI, to stimulate prothrombotic and proinflammatory activity of immune cells in vitro. METHODS: Peripheral blood mononuclear cells (PBMCs) from 11 healthy individuals were incubated with: (1) "anti-D1(+)"-pooled plasma derived from patients suspected of having APS contained anticardiolipin antibodies (aCL), lupus anticoagulant (LA), anti-β2GPI and anti-D1 β2GPI; (2) "anti-D1(-)"-pooled plasma from patients suspected of having APS contained aCL, LA, anti-β2GPI, and negative for anti-D1 β2GPI; (3) "seronegative"-negative for aPL. RESULTS: The presence of anti-D1(+) and anti-D1(-) plasma resulted in increased HLA-DR and CD11b on monocytes. While only anti-D1(+) plasma markedly increased the percentage and median fluorescence intensity (MFI) of CD142 (tissue factor, TF) on monocytes in comparison with those cultured with anti-D1(-) and seronegative plasma. Anti-D1(+) plasma resulted in increased percentage and MFI of activation marker CD69 on NK and T cytotoxic cells. Expression of IgG receptor FcγRIII(CD16) on monocytes and NK cells was down-regulated by the anti-D1(+) plasma. CONCLUSIONS: Taking together, our study shows the ability of patient-derived aPL to induce immune cell activation and TF expression on monocytes. For the first time, we demonstrated the influence of anti-D1 β2GPI on the activation status of monocytes, NK and cytotoxic T cells. Our findings further support a crucial role of D1 epitope in the promotion of thrombosis and obstetrical complications in APS.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Martirosyan, Anush $u Laboratory of Molecular and Cellular Immunology, Institute of Molecular Biology NAS RA, 7 Hasratyan St., 0014, Yerevan, Armenia.
- 700 1_
- $a Slavik, Ludek $u Department of Hemato-oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and Faculty Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Margaryan, Sona $u Laboratory of Molecular and Cellular Immunology, Institute of Molecular Biology NAS RA, 7 Hasratyan St., 0014, Yerevan, Armenia. Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc and Faculty Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Ulehlova, Jana $u Department of Hemato-oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and Faculty Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Mikulkova, Zuzana $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc and Faculty Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Hlusi, Antonin $u Department of Hemato-oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and Faculty Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Papajik, Tomas $u Department of Hemato-oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and Faculty Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Kriegova, Eva $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc and Faculty Hospital, Olomouc, Czech Republic.
- 773 0_
- $w MED00203201 $t Auto- immunity highlights $x 2038-0305 $g Roč. 11, č. 1 (2020), s. 5
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32127041 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20210121103836 $b ABA008
- 999 __
- $a ind $b bmc $g 1524013 $s 1095138
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 11 $c 1 $d 5 $e 20200302 $i 2038-0305 $m Auto- immunity highlights $n Auto Immun Highlights $x MED00203201
- GRA __
- $a SCS 18T-1F396 $p State Committee of Science
- GRA __
- $a MZ CR VES15-28659A, in part IGA UP_2018_016 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a MH CZ - DRO (FNOL, 00098892). $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20200511